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Combination  vaccines  against  diphtheria,  tetanus  and  pertussis  (DTP)  represent  the  core  of  childhood
vaccination  programs.  Quinvaxem,  a fully-liquid,  pentavalent  combination  vaccine  containing  inactiv-
ated  hepatitis  B  (HepB),  Haemophilus  inﬂuenzae  type  b  (Hib)  and  whole-cell  pertussis  (wP)  antigens,  and
tetanus  and  diphtheria  toxoids,  has  been  shown  to be suitable  for  boosting  children  primed  in infancy
with  another  DTwP–HepB–Hib  vaccine.  This  single-blind,  randomized,  controlled  study  was designed
to  demonstrate  non-inferiority  of  a primary  vaccination  course  (6–10–14  week  schedule)  of Tritanrix
HB  +  Hib  (ﬁrst  dose)  and  Quinvaxem  (second/third  doses)  versus  three  doses  of  Quinvaxem  with  respect
to  the  seroprotection/seroconversion  rates  for all  antigens  one  month  after  vaccination  course  com-
pletion.  Four  hundred  healthy  subjects  eligible  for the  local  Expanded  Program  on Immunization  were
enrolled  and  equally  randomized  to the  two  treatment  regimens.  All  subjects  achieved  seroprotection
for  tetanus  and  Hib,  all except  one  for  diphtheria,  and  all  except  two  achieved  seroconversion  against
Bordetella  pertussis.  Seroprotection  against  hepatitis  B was  achieved  by  97.4%  of  Tritanrix  HB  +  Hib fol-
lowed  by  Quinvaxem  and  94.9%  of  Quinvaxem  subjects.  Therefore,  one  month  after  vaccination  course
completion,  seroprotection  rates  (seroconversion  rate  for B.  pertussis)  of Tritanrix  HB  +  Hib  followed  by
Quinvaxem  were  non-inferior  to those  elicited  by Quinvaxem  only,  thus  meeting  the  primary  objective.
Adverse  events  were  comparable  between  the  groups  and  were  in  line  with  the  safety  proﬁle  of  the vac-
cines.  The  switch  of  vaccine  had  no  apparent  effect  on  safety  endpoints.  Our  results  support  the use of
Quinvaxem  interchangeably  with  Tritanrix  HB  + Hib  in  a  primary  vaccination  course  and  provides  further
evidence  for  the  interchangeability  of pentavalent  vaccines  (Clinical  Trials.gov  registry:  NCT01357720).
 201©
. Introduction
Combination vaccines against diphtheria, tetanus and pertussis
DTP) represent the core of global childhood vaccination programs.
he introduction of hepatitis B (HepB) virus and Haemophilus
nﬂuenzae type b (Hib) vaccinations into the Expanded Program on
mmunization (EPI) in the 1990s has ensured that >70% of the tar-
eted population receives the necessary vaccines [1]; yet, in 2009
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over 23 million children worldwide still did not receive all three
DTP doses [2], and vaccine coverage for HepB and Hib was at sub-
optimal levels in many countries.
Pediatric combination vaccines that include DTP with other
antigens (HepB surface antigen [HBsAg] and Hib) simplify immu-
nization delivery providing multiple advantages to children,
parents, and health care providers by reducing the number of injec-
tions, clinical visits, and logistic requirements [3]. Currently six
pentavalent vaccines are pre-qualiﬁed by the WHO  and in use in the
EPI: liquid Quinvaxem (Berna Biotech Korea Corporation), liquid
PentavacTM (Serum Institute of India Ltd.), liquid DTwP–HepB–Hib
(Biological E Limited), lyophilized DTwP–HepB/Hib (Biological E
Limited), Euforvac-HibTM (LG Life Sciences) and lyophilized Tritan-
Open access under CC BY-NC-ND license.rix HB + Hiberix (GlaxoSmithKline Biologicals).
Although aP vaccines, developed in the 1980s, have gradually
become the dominant type in the industrialized world, wP vac-
cines are still the most commonly used pertussis vaccines among
license.
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he global population [4]. The higher development and production
osts of aP vaccines, resulting in higher prices per dose, have out-
eighed their improved tolerability proﬁle making wP vaccines
till the ﬁrst choice in most developing countries [5].
The  United Nations Children’s Fund (UNICEF) supplies vaccines
o 58% of the world’s children [6]. UNICEF aims to guarantee vaccine
upply [7] in the event of a vaccine shortage to allow continuation
f immunization programs; alternative suppliers may  be sought, or
accine deliveries may  be prioritized. If alternate vaccines are sup-
lied to a country it is theoretically possible that switching between
accines from different manufacturers occurs. Such situations are
ore likely to occur when there are a limited number of suppliers,
nd at present the number of suppliers of WHO  pre-qualiﬁed pen-
avalent vaccines is limited to ﬁve [8]. In 2012, UNICEF procured
oth fully liquid and lyophilized pentavalent vaccines in different
resentations from all four manufacturers, however in 2006 and
007 pentavalent vaccines were available from only two manufac-
urers [9]. It is therefore unrealistic to assume that the same vaccine
ill always be available for each child [10].
Few guidelines are available on vaccine interchangeability
11,12].  The WHO  recommends that the same wP  vaccine should
e given throughout a primary vaccination course [5], but have
dopted the position that if the previous type of vaccine is unknown
r unavailable, any wP-containing vaccine (or aP-containing vac-
ine) may  be used for subsequent doses [5]. It is clear that the
nterchangeability of prequaliﬁed wP vaccines is poorly studied; it
as to our knowledge only been studied with respect to the inter-
hangeability of a lyophilized DTwP–HBV/Hib vaccine in a primary
ourse with a fully-liquid DTwP–HBV–Hib vaccine (Quinvaxem) as
 booster [13]. This demonstrated that Quinvaxem can be used for
oosting children primed in infancy with another DTwP–HepB–Hib
accine. Currently no data are available on wP-containing penta-
alent vaccine interchangeability within a primary vaccine course.
ur study was designed to answer this question with respect to the
wo wP containing pentavalent vaccines: Quinvaxem and Tritanrix
B + Hiberix.
The primary objective was to show the non-inferiority of a
rimary vaccination course consisting of one dose of Tritanrix
B + Hiberix (Tritanrix HB + Hib) followed by Quinvaxem as the sec-
nd and third dose versus three doses of Quinvaxem with respect
o the seroprotection/seroconversion rates for all antibodies one
onth after completion of a 6–10–14 week vaccination course.
afety was also evaluated.
.  Materials and methods
This  phase IV, single-blind (observer-blinded), randomized,
omparator-controlled study was conducted at the Research Insti-
ute for Tropical Medicine (RITM), Muntinlupa City, Philippines
etween 30 May  2011 and 30 September 2011. Prior to com-
encement, the Philippines Food and Drug Administration (PFDA),
nd the Institutional Review Board of the RITM approved the
tudy, which was performed in accordance with the Decla-
ation of Helsinki and Good Clinical Practice standards. This
tudy was registered under ClinicalTrials.gov NCT01357720. Par-
nts/legal guardians gave written informed consent for all
articipants. Healthy children aged 42–62 weeks with a birth
ose of HepB vaccination were included. Exclusion criteria
ncluded: treatment with an investigational medicinal prod-
ct or parenteral immunoglobulins/blood products (since birth),
lanned administration of a vaccine not in the study pro-
ocol, immunodeﬁciency/immunosuppressive therapy, previous
ib/DTP vaccination, history of anaphylaxis/serious vaccine reac-
ion, allergy to vaccine components, or participation in another
linical study.ne 32 (2014) 888– 894 889
After screening, children were randomized sequentially 1:1 to
receive either one 0.5 mL  dose of Tritanrix HB + Hib followed by two
0.5 mL  doses of Quinvaxem (Tritanrix HB + Hib + Quinvaxem group)
or three 0.5 mL  doses of Quinvaxem (Quinvaxem only group),
according to a randomization schedule using sealed envelopes.
Vaccine preparation and administration were performed by inde-
pendent personnel to maintain observer blinding (investigator).
Tritanrix HB + Hib was  composed of Hiberix (lot number:
A72CA647B) reconstituted using a liquid suspension of Tritanrix
HB (lot number: AT15B656BD, both GlaxoSmithKline Biologicals).
After reconstitution, a 0.5 mL dose contained ≥30 IU diphtheria tox-
oid, ≥60 IU tetanus toxoid, ≥4 IU inactivated Bordetella pertussis,
10 g Hib polysaccharide conjugated to tetanus toxoid (∼25 g)
as a carrier, and 10 g HBsAg. Each 0.5 mL  dose of Quinvaxem
(lot number: 0451523, Berna Biotech Korea Corporation) contained
≥30 IU diphtheria toxoid, ≥60 IU tetanus toxoid, ≥4 IU inactivated
B. pertussis, 10 g Hib polysaccharide conjugated to CRM197 pro-
tein (∼25 g), and 10 g HBsAg. Study vaccines were administered
intramuscularly into the anterolateral thigh using a tuberculin
syringe (length 16 mm)  according to the local 6–10–14-week EPI
schedule (visits 1–3, respectively).
2.1.  Immunogenicity evaluation
For  immunogenicity assessments 3 mL  blood was taken at visit 1
(before the ﬁrst dose) and visit 4 (one month after the third dose).
In-house assays were used for all antigens. Anti-HepB antibodies
were measured by Novartis Vaccines and Diagnostics, Marburg,
Germany using an indirect ELISA with seroprotection deﬁned as
a concentration of HepB antibodies ≥10 IU/mL. The University of
Rochester, New York, USA used a competitive ELISA to measure
antibodies against Hib PRP with seroprotection rates deﬁned by the
two  cut-off levels of ≥0.15 g/mL and ≥1.0 g/mL, and an indirect
ELISA for diphtheria and tetanus antibodies with seroprotection
deﬁned as a concentration of ≥0.1 IU/mL. B. pertussis antibodies
were analyzed using a whole cell ELISA at the University of Turku,
Finland. As there is no deﬁnition of seroprotection for B. pertussis,
seroconversion was  deﬁned as either concentrations ≥20 EU/mL or
a ≥4-fold increase from pre-vaccination levels.
Primary endpoints at visit 4 were the percentage of subjects
achieving the immunogenicity parameters deﬁned above, with the
exception of PRP at the higher cut-off level of ≥1.0 g/mL, which
was a secondary endpoint.
2.2.  Safety evaluation
Solicited  local (tenderness, erythema, and induration) and sys-
temic (fever ≥38 ◦C) AEs after each vaccination were documented
by parents/legal guardians for ﬁve days (starting on the day of vac-
cination) in a subject diary, together with any unsolicited AE. At
each study visit the investigator asked a non-leading question to
collect unsolicited AEs. Reported SAEs were recorded for up to 6
months after the ﬁnal vaccination. AEs were graded as mild, mod-
erate or severe. Whilst blinded to study vaccine, the investigator
determined the possible cause of any AE and any potential rela-
tionship to study vaccine administration.
2.3. Statistical analysis
Assuming  a seroprotection/seroconversion rate for each anti-
gen of 95% in each group and a clinically signiﬁcant non-inferiority
limit of −10%, a sample size of 360 evaluable subjects was required
to demonstrate, with an overall power of >90% and a 1-sided sig-
niﬁcance level of 2.5%, the non-inferiority of Quinvaxem given
interchangeability with Tritanrix HB + Hib. Assuming a dropout rate
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f approximately 10%, a sample size of 400 subjects (200 in each
roup) was set.
The  primary and secondary analyses were performed with
oth the according-to-protocol (ATP) and intention-to-treat (ITT)
opulations. Descriptive safety analyses were performed on all
ubjects who received at least 1 injection of study vaccine (safety
opulation).
The study hypothesis is as follows:
 Null hypothesis: The seroprotection/seroconversion rate for at
least 1 antigen 1 month after 1 dose of Tritanrix HB + Hib fol-
lowed  by Quinvaxem as the 2nd and 3rd dose is inferior to the
seroprotection/seroconversion rate 1 month after 3 vaccinations
with  Quinvaxem by more than −10%.
 Alternative hypothesis: The seroprotection/seroconversion rate for
all antigens 1 month after 1 dose of Tritanrix HB + Hib followed
by  Quinvaxem as the 2nd and 3rd dose is not inferior to the sero-
protection/seroconversion rate 1 month after 3 vaccinations with
Quinvaxem by more than 10%.
The  non-inferiority of Quinvaxem given interchangeably with
ritanrix HB + Hib compared with a full vaccination course of
uinvaxem would be demonstrated if the lower limit of all two-
ided 95% conﬁdence intervals (CIs; Newcombe–Wilson score
ethod without continuity correction) of the difference in sero-
rotection/seroconversion rates between the two  groups were
imultaneously greater than −10%. If non-inferiority was demon-
trated, the two-sided Fisher’s exact test was performed.
.  Results
.1. Study population
Fig.  1 shows the patient disposition. A total of 402 subjects were
creened, and 400 subjects randomized equally to both groups (two
ubjects did not meet all inclusion/exclusion criteria). Altogether,
96 subjects (99.0%) received all three vaccinations. The mean
ge was 6.7 (Tritanrix HB + Hib + Quinvaxem group) and 6.8 weeks
Quinvaxem only group). Table 1 presents other demographic data.
.2. Immunogenicity data
Immunogenicity  results for the ATP population are given (ITT
opulation results were similar). At baseline, the majority of sub-
ects were seroprotected at the lower cut off level of ≥0.15 g/mL in
oth treatment groups for Hib (TritanrixTM HB + Hib + Quinvaxem
3.8% and Quinvaxem 84.8%). For tetanus toxoid, 88.7% of Tri-
anrix HB + Hib + Quinvaxem subjects and 91.9% of Quinvaxem
ubjects were seroprotected at baseline. For HepB almost one-
hird of subjects were seroprotected at baseline (TritanrixTM
B + Hib + Quinvaxem 27.3% and Quinvaxem 30.8%), and for diph-
heria less than one-ﬁfth of subjects were seroprotected (Tritanrix
B + Hib + Quinvaxem 17% and Quinvaxem 16.7%).
One  month after the third dose of vaccine, all subjects had
chieved seroprotection for tetanus and Hib (100% for both antigens
or both treatment groups), all except one for diphtheria (100% for
ritanrix HB + Hib + Quinvaxem and 99.5% for Quinvaxem), and all
chieved seroconversion against B. pertussis except for two  subjects
100% for Tritanrix HB + Hib + Quinvaxem and 99% for Quinvaxem).
eroprotection against hepatitis B was achieved in 97.4% of Tritan-
ix HB + Hib + Quinvaxem and 94.9% of Quinvaxem subjects (Fig. 2).The non-inferiority of Quinvaxem given interchangeably with
ritanrix HB + Hib compared with a full vaccination course
f Quinvaxem was demonstrated. For all individual antigens,
he lower limits of the two-sided CIs of the differences inne 32 (2014) 888– 894
seroprotection/seroconversion rates between the two groups were
all greater than −10% (Fig. 3).
3.3. Safety data
For  both groups, fewer solicited local AEs were reported after
the third vaccination than after the ﬁrst or second (Fig. 4).
Tenderness (injection site pain) was the most common local
solicited AE, but was experienced by more subjects in the Tritanrix
HB + Hib + Quinvaxem group after the ﬁrst (64.0% vs. 54.0%), sec-
ond (62.1% vs. 54.3%) and third (44.2% vs. 38.2%) vaccinations than
in the Quinvaxem only group. The majority of solicited local AEs
were of mild to moderate severity. After the ﬁrst vaccination, more
subjects who  had received Tritanrix HB + Hib reported severe local
AEs than subjects who had received Quinvaxem (6 vs. 3 subjects).
The incidence of fever (solicited systemic AE) (Fig. 4) was lower
after the third vaccination compared to the ﬁrst or second vaccina-
tion in both groups. The majority of cases of fever resolved within
one day of onset. The incidences of unsolicited AEs after individ-
ual vaccinations were similar in both groups ranging from 14.0%
to 19.8% in the Tritanrix HB + Hib + Quinvaxem and from 12.0% to
19.6% in the Quinvaxem only group. Upper respiratory tract infec-
tions were most frequently reported; most unsolicited AEs were of
mild severity.
Two  subjects, both in the Tritanrix HB + Hib + Quinvaxem group,
experienced SAEs: one subject died (severe respiratory failure sec-
ondary to severe pneumonia secondary to severe viral encephalitis
starting one week after the third Quinvaxem vaccination), the other
was  withdrawn from the study (idiopathic thrompocytopoenic
purpura developing 12 days after vaccination with Tritanrix
HB + Hib). All SAEs were considered unrelated to the study vaccines.
4. Discussion
This study provides scientiﬁc evidence on the interchangeabil-
ity of wP pentavalent vaccines in a primary vaccination course in
infants according to a 6–10–14 week schedule. Our most impor-
tant ﬁnding is that Quinvaxem given interchangeably with Tritanrix
HB + Hib was  shown to be non-inferior to a full vaccination course
of Quinvaxem. Seroprotection rates for all antigens and serocon-
version rates for pertussis were high, with most if not all subjects
achieving seroprotection or seroconversion one month after the
third vaccination, irrespective of the vaccination group.
Immune responses observed in our study to TritanrixTM
HB + Hib + Quinvaxem were comparable to responses seen in pre-
vious studies with TritanrixTM HB + Hib only [14,15] or Quinvaxem
only regimens [3]. In our study, a high percentage of infants
(88.7–91.9%) were seroprotected at baseline against tetanus. In
1999, the Maternal and Neonatal Tetanus (MNT) Elimination Ini-
tiative was  jointly set up by the WHO  and UNICEF, aiming to
eliminate MNT  in those countries which had not yet done so
[16]. The Philippines has an active maternal tetanus immunization
program, and although MNT  has not yet been eliminated, the per-
centage coverage of protection at birth against neonatal tetanus has
increased over the last years from 22% in 2009 to 39% in 2011 [17].
The high percentage of seroprotection against tetanus observed
in infants included in our study is possibly attributable to this.
Additionally, the baseline seroprotection rate against Hib was also
high, at 83.0–84.8%. This is in line with data reported in the lit-
erature. In one study with TritanrixTM HB + Hib in Filipino infants,
Hib seroprotection rates of 64.5–65.3% were reported [14]. Further-
more, Ortega-Barrìa et al. [18] report on the results of four phase
III studies using a novel pentavalent combination vaccine com-
pared with TritanrixTM HB + Hib conducted in Panama/Nicaragua,
Turkey, Belgium and the Philippines. The baseline seroprotection
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One month post-vaccination
blood sampling, Day 85
Completed study: 195 (97.5%)
Total discontinued: 5 (2.5%)
Adverse event: 1 (0.5%)
Consent withdrawal: 1 (0.5%)
Migrated/moved: 2 (1.0%)
Death: 1 (0.5%)
Excluded from:
Safety analysis: 0
ITT analysis: 5 (2.5%)
ATP analysis: 6 (3.0%)
One month post-vaccination
blood sampling, Day 85
Completed study: 198 (99.0%)
Total discontinued: 2 (1.0%)
Adverse event: 0
Consent withdrawal: 1 (0.5%)
Migrated/moved: 1 (0.5%)
Death: 0
Excluded from:
Safety analysis: 0
ITT analysis: 2 (1.0%)
ATP analysis: 2 (1.0%)
Discontinued:
Migrated/moved: 1 (0.5%)
Discontinued:
Death: 1 (0.5%)
Consent w/drawal: 1 (0.5%)
Third vaccination, Day 57
Quinvaxem
N = 197
Third vaccination, Day 57
Quinvaxem
N = 199
Second vaccination, Day 29
Quinvaxem
N = 199
Discontinued:
Migrated/moved: 2 (1.0%)
Second vaccination, Day 29
Quinvaxem
N = 199
Subjects enrolled and randomized
N = 400
pre-vaccination blood sampling
First vaccination, Day 1
Tritanrix HB+Hib
N = 200
First vaccination, Day 1
Quinvaxem
N = 200
Discontinued:
Adverse event: 1 (0.5%)
Discontinued:
Consent withdrawal: 1 (0.5%)
Fig. 1. Patient disposition. ATP = according-to-protocol; ITT = intention-to-treat; N = number of subjects in speciﬁed category.
Table 1
Baseline demographic data (safety population).
TritanrixTM HB + Hib + Quinvaxem Quinvaxem only Total
N  = 200 N = 200 N = 400
Sex (n, %) Female 95 (47.5%) 99 (49.5%) 194 (48.5%)
Male  105 (52.5%) 101 (50.5%) 206 (51.5%)
Age  (weeks) Median (min, max) 6 (6, 9) 7 (6, 9) 6 (6, 9)
Mean  ± SD 6.7 (0.86) 6.8 (0.91) 6.7 (0.89)
Weight  (kg) Median (min, max) 4.5 (3.1, 6.2) 4.5 (3.1, 6.0) 4.5 (3.1, 6.2)
Height  (cm) Median (min, max) 55 (50, 61) 55 (50, 62) 55 (50, 62)
BMI  (kg/m2) Median (min, max) 14.9 (10.2, 18.8) 15.2 (10.2, 20.3) 15.1 (10.2, 20.3)
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Fig. 2. Seroprotection/seroconversion rates (seroconversion rate for pertussis only) of Tritanrix HB + Hib followed by Quinvaxem and Quinvaxem only at baseline and visit
4  (one month after the third vaccination).
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Fig. 3. Treatment difference for seroprotection/seroconversion shows that Tritanrix HB + Hib followed by Quinvaxem is non-inferior to Quinvaxem only. Hib: H. inﬂuenzae
type b. –: margin of non-inferiority. Error bars indicate 2-sided 95% conﬁdence intervals. All values are non-signiﬁcant based on two-sided Fisher’s exact test.
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Fig. 4. Solicited local and systemic adverse events after the ﬁrst, second and third vaccinations for Tritanrix HB + Hib followed by Quinvaxem and Quinvaxem only. Fever:
body temperature ≥38 ◦C.
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ates against Hib were 62.4–63.6% in the Philippines – much higher
han values reported in the other countries (19.6–47.1%). However,
o explanation for these high levels was provided.
Our results also show that switching from Tritanrix HB + Hib to
uinvaxem had no negative impact with regards to safety; AE pat-
erns were comparable between the groups and well in line with
hose observed in earlier studies with Quinvaxem [3].
The  current study was conducted to provide data on the inter-
hangeability of wP pentavalent vaccines in a primary vaccination
ourse. Until now, only the interchangeability of wP  pentavalent
accines as a booster has been studied [13]. Substituting a booster
ose of a lyophilized pentavalent vaccine with that of a fully liquid
ne was shown to be highly immunogenic with a favorable safety
roﬁle. It is, however, clear that there is limited interchangeability
ata available. The interchangeability of the individual compo-
ents of pentavalent vaccines, as well as for aP-containing vaccines
as been shown [11,12,19–24]. Although data for aP containing
accines is limited, their interchangeability is supported by the
dvisory Committee on Immunization Practices (ACIP) in the USA
25] and the Public Health Agency of Canada (PHAC) [26]. The rec-
mmendations given by ACIP and the PHAC were put in place
ecause both the USA and Canada use pentavalent vaccines from
ore than one manufacturer, and it is possible that different prod-
cts may  be used in one individual during a vaccination course as
 result, for example, of migration or vaccine shortages. It has also
een shown that in a vaccine shortage situation 25% of children
hose vaccination was deferred did not return for the indicated
accine [26], leaving a population of children partially vaccinated
nd susceptible to disease.
A  reason for the limited published data may  be attributable to
he fact that interchangeability is particularly difﬁcult to study.
f we consider that there are six WHO  pre-qualiﬁed pentavalent
accines, and three doses in a primary vaccine course, then there
re 125 theoretically possible permutations of vaccine doses. The
hances of any particular permutation having been studied are very
ow. As stated by Decker [10]: “once we are faced with multiple
ombination vaccines, the likelihood shrinks that any particular
ubstitution will have been studied explicitly”. We  studied only one
f 8 possible permutations using the two vaccines, and it is unre-
listic to assume that all 8 should be tested and more so that all
25 be tested. Halsey, in his 1995 paper entitled: “Practical consid-
rations regarding the impact on immunization schedules of the
ntroduction of new combined vaccines”, discussed the inherent
roblems related to the increasing number of combined childhood
accines available and in turn, the increasing number of potential
ermutations. The evaluation of all potential permutations has to
e balanced against the cost of running clinical trials. At the time he
rovided a conservative estimate on the cost of running one clinical
rial to evaluate one possible permutation from all available combi-
ation vaccines at the time at between $100,000 and $300,000 [27].
f this is applied to all combinations of the pentavalent vaccines
vailable on the current market, it equates to $12.5–37.5 million
o evaluate all 125 permutations. Bearing in mind that this is an
stimate based on 1995 ﬁgures, the cost in today’s market would
ikely be considerably in excess of this ﬁgure.
The WHO  have stated that in principle the same wP-containing
r aP-containing vaccine should be given throughout a primary
ourse of vaccination and state that available data does not sug-
est that changing between an aP-containing and wP-containing
accine interferes with safety or immunogenicity [5]. Thus, if the
revious type of vaccine is unknown or unavailable, any wP  vaccine
r aP vaccine may  be used for subsequent doses to complete a pri-
ary vaccination course started with either an aP or wP vaccine [5].
ur data support this, and show that changing from one wP vaccine
o another after the ﬁrst dose does not impact immunogenicity or
afety.ne 32 (2014) 888– 894 893
In 2010, one of the available pentavalent vaccines at the time,
Shan5, lost the WHO  pre-qualiﬁcation status. This created a short-
age of pentavalent vaccines. In order to continue immunization
programs that were underway, the WHO  recommended, that for
children who had begun but not completed an immunization
schedule with Shan5, an alternative vaccine or vaccines be used
to complete the schedule [28]. This is an example of a situation, in
which pentavalent vaccines have been used interchangeably.
Despite the complexities of studying interchangeability, efforts
should be made to study other available pentavalent vaccines in
combination to increase the limited body of evidence on inter-
changeability in a primary vaccine course. This would beneﬁt those
making vital vaccine decisions in areas where vaccination is most
needed.
5. Conclusions
Our results show that Quinvaxem can replace the second and
third dose of a primary vaccination course started with Tritanrix
HB + Hib without impacting immunogenicity or having any nega-
tive effect on safety and tolerability. Our ﬁndings provide scientiﬁc
evidence supporting the interchangeability of Quinvaxem with
other pentavalent vaccines, or components thereof.
Acknowledgements
This study was  sponsored by Crucell Switzerland AG. We  would
like to thank Lyndsey Kostadinov (Crucell Switzerland AG) for writ-
ing the manuscript. We  would also like to thank all participants of
the study.
Conﬂicts of interest/disclosures: C. Jica, A. Macura-Biegun and M.
Rauscher are employees of Crucell Switzerland AG.  E. Alberto has
no conﬂicts of interests to declare. M.R.Z. Capeding has received
speaker honoraria, travel and research grants from Pﬁzer Inc., Glax-
oSmithKline, Sanoﬁ Pasteur and Novartis and a research grant from
Crucell Switzerland AG for this clinical study. Contributions: C. Jica
was  involved in study design and analysis, and critically reviewed
the manuscript. A. Macura-Biegun provided signiﬁcant intellectual
contribution and critically reviewed the manuscript. M.  Rauscher
was involved in analysis of safety data, manuscript writing, and
critically reviewed the manuscript. M.R.Z. Capeding was the prin-
cipal investigator and E. Alberto co-investigator, and both were
involved in data collection, manuscript writing and critical review.
All authors approved the ﬁnal version of the manuscript. Role of
the funding source: Crucell Switzerland AG was involved in study
design, analysis and interpretation of data, writing of the report
and in the decision to submit the article for publication.
References
[1] World Health Organization. Global Immunization Vision and Strategy
(GIVS) 2006–2015. Available at: http://whqlibdoc.who.int/hq/2005/WHO
IVB 05.05.pdf [accessed 14.05.13].
[2] World Health Organization. Global Immunization Vision and Strategy.
Progress report and strategic direction for the Decade of Vaccines. Available
at: http://apps.who.int/gb/ebwha/pdf ﬁles/WHA64/A64 14-en.pdf [accessed
05.06.13].
[3]  Schmid DA, Macura-Biegun A, Rauscher M.  Development and introduction
of a ready-to-use pediatric pentavalent vaccine to meet and sustain the
needs of developing countries – Quinvaxem (R): the ﬁrst 5 years. Vaccine
2012;30:6241–8.
[4] World Health Organisation, UNICEF. Immunization Summary. Available
at: http://www.childinfo.org/ﬁles/immunization summary 2012 en.pdf
[accessed 05.06.13].
[5] World Health Organization. Pertussis vaccines: WHO  position paper. Wkly Epi-
demiol Rec 2010;85:385–400.
[6] UNICEF. Immunization. Available at: http://www.unicef.org/immunization/
index 2819.html [accessed 05.06.13].
[7] UNICEF. Supplies and Logistics. Available at: http://www.unicef.org/supply/
[accessed  05.06.13].
8  Vacci
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
schedules of the introduction of new combined vaccines. Ann N Y Acad Sci94 M.R.Z.  Capeding et al. /
[8] World Health Organisation. WHO  Prequaliﬁed Vaccines. Available at:
http://www.who.int/immunization standards/vaccine quality/PQ vaccine
list en/en/index.html [accessed 05.06.13].
[9] UNICEF. Contact Awards. Available at: http://www.unicef.org/videoaudio/
PDFs/contract awards April 2012.pdf [accessed 19.12.12].
10] Decker MD.  Principles of pediatric combination vaccines and practical issues
related to use in clinical practice. Pediatr Infect Dis J 2001;20:S10–8.
11] Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J 2001;20:S23–9.
12] Greenberg DP, Feldman S. Vaccine interchangeability. Clin Pediatr (Phila)
2003;42:93–9.
13]  Suarez E, Asturias EJ, Hilbert AK, Herzog C, Aeberhard U, Spyr C. A fully liquid
DTPw–HepB–Hib combination vaccine for booster vaccination of toddlers in El
Salvador. Rev Panam Salud Publica 2010;27:117–24.
14]  Gatchalian SR, Ramakrishnan G, Bock HL, Lefevre I, Jacquet JM.  Immunogenic-
ity, reactogenicity and safety of three-dose primary and booster vaccination
with combined diphtheria–tetanus–whole-cell pertussis–hepatitis B-reduced
antigen content Haemophilus inﬂuenzae type b vaccine in Filipino children. Hum
Vaccin 2010;6:664–72.
15] Espinoza F, Tregnaghi M,  Gentile A, Abarca K, Casellas J, Collard A, et al. Primary
and booster vaccination in Latin American children with a DTPw–HBV/Hib
combination: a randomized controlled trial. BMC  Infect Dis 2010;10:297.
16] UNICEF. Elimination of Maternal and Neonatal Tetanus. Available at:
http://www.unicef.org/health/index 43509.html [accessed 06.06.13].
17] World Health Organization. WHO  Vaccine-Preventable Diseases: Monitoring
System – The Philippines. Available at: http://apps.who.int/immunization
monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B
%5D=PHL [accessed 06.06.13].
18] Ortega-Barria E, Kanra G, Leroux G, Bravo L, Safary A, Lefevre I. The immuno-
genicity and reactogenicity of DTPw–HBV/Hib 2.5 combination vaccine:
results from four phase III multicenter trials across three continents. Vaccine
2007;25:8432–40.
19]  Anderson EL, Decker MD,  Englund JA, Edwards KM,  Anderson P, McInnes P,
et al. Interchangeability of conjugated Haemophilus inﬂuenzae type b vaccines
in infants. J Am Med  Assoc 1995;273:849–53.
[ne 32 (2014) 888– 894
20] Scheifele D, Law B, Mitchell L, Ochnio J. Study of booster doses of two
Haemophilus inﬂuenzae type b conjugate vaccines including their interchange-
ability. Vaccine 1996;14:1399–406.
21] Greenberg DP, Pickering LK, Senders SD, Bissey JD, Howard RA, Blatter MM,
et al. Interchangeability of 2 diphtheria–tetanus–acellular pertussis vaccines
in infancy. Pediatrics 2002;109:666–72.
22] Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM,
et al. Interchangeability of two diphtheria and tetanus toxoids, acellular
pertussis, inactivated poliovirus, Haemophilus inﬂuenzae type b conjugate
vaccines as a fourth dose in 15–20-month-old toddlers. Vaccine 2006;24:
4017–23.
23] Kwak GY, Kwon HJ, Kim JH, Kim HM,  Park JS, Ma  SH, et al. The immunogenic-
ity and safety of DTaP interchangeable immunization among Korean children.
Vaccine 2012;30:4644–7.
24] Langley JM, Halperin SA, Rubin E, White C, McNeil S, Mutch J, et al.
Safety and immunogenicity of 2 mixed primary infant immunization sched-
ules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated
poliomyelitis, and Haemophilus inﬂuenzae type B vaccines at 2, 4, and 6
months of age: a randomized controlled trial. Pediatr Infect Dis J 2012;31:
189–92.
25]  Centers for Disease Control and Prevention. General Recommendations on
Immunization: Recommendations of the Advisory Committee on Immuniza-
tion Practices (ACIP). MMWR  Morb Mortal Wkly Rep;60:1–61.
26] Public Health Agency of Canada. National Advisory Committee on Immu-
nization. Canadian Immunization Guide: Seventh Edition – 2006. Prin-
ciples of Vaccine Interchangeability. Available at: http://www.phac-aspc.
gc.ca/publicat/cig-gci/ [accessed 05.06.13].
27] Halsey NA. Practical considerations regarding the impact on immunization1995;754:250–4.
28]  World Health Organization. Shan5 vaccine delisted from WHO  prequali-
ﬁcation. Available at: http://www.who.int/immunization standards/vaccine
quality/shan5 who  statement 27july10.pdf [accessed 25.05.13].
